Multiple Sclerosis

TYSABRI's Benefits Continue to Drive Product's Growth with More Than 31,800 Patients Receiving Treatment

Cambridge, MA and Dublin, Ireland, July 22, 2008 -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the two-year anniversary of TYSABRI® (natalizumab) as a treatment for relapsing forms of multiple sclerosis (MS), marking the reintroduction of the product in the United States (US) and the first international approval. The companies estimate that as of the end of June 2008, more than 31,800 patients worldwide are receiving TYSABRI treatment.

Specifically, as of the end of June 2008:

* In the US, more than 17,800 patients are on TYSABRI commercially and more than 3,100 physicians have prescribed the therapy;    » read more »

September 26, 2007 -- Genzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).    » read more »

Study Published in Annals of Neurology